 Connection
Jesus Delgado-Calle to Drug Resistance, Neoplasm
This is a "connection" page, showing publications Jesus Delgado-Calle has written about Drug Resistance, Neoplasm.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.494 |
|
|
|
-
Sabol HM, Paxton BC, Anloague A, Kaur J, Nester MR, Khan S, Smith J, Croucher PI, McDonald MM, Montgomery CO, Stambough JB, Barnes CL, Ambrogini E, Ebetino FH, Schinke C, Ashby C, Delgado-Calle J. Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells. J Exp Clin Cancer Res. 2026 Jan 05; 45(1):31.
Score: 0.784
-
Sabol HM, Ashby C, Adhikari M, Anloague A, Kaur J, Khan S, Choudhury SR, Schinke C, Palmieri M, Barnes CL, Ambrogini E, Nookaew I, Delgado-Calle J. A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma. Haematologica. 2024 08 01; 109(8):2606-2618.
Score: 0.710
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|